Active, not recruitingInterventional · Phase 2NCT03371719 ↗A Phase II, Double-Blinded, Placebo-Controlled Randomized Trial of Salvage Radiotherapy With or Without Enhanced Anti-Androgen Therapy With Apalutamide in Recurrent Prostate Cancer (BALANCE*)
Active, not recruitingInterventional · Phase 2NCT03725761 ↗A Multi-arm, Phase 2 Study to Evaluate the Safety and Efficacy of Sacituzumab Govitecan in Patients With Metastatic Castration-Resistant Prostate Cancer Who Have Progressed on Second Generation AR-Directed TherapyScott T. TagawaPIInterventionDrug: Sacituzumab GovitecanDatesOct 2018 – Apr 2024· Results postedSponsorUniversity of WisconsinProstate Cancer
RecruitingInterventional · Phase 2NCT03866382 ↗A Phase II Study of Ipilimumab, Cabozantinib, and Nivolumab in Rare Genitourinary Cancers (ICONIC)Cora SternbergPIInterventionProcedure: Biospecimen Collection · Procedure: Bone Scan · Drug: Cabozantinib S-malate · Procedure: Computed Tomography · Procedure: Echocardiography Test · Biological: Ipilimumab · Procedure: Magnetic Resonance Imaging · Biological: Nivolumab · Procedure: Positron Emission TomographyDatesMay 2019 – Feb 2027 (est.)SponsorAlliance for Clinical Trials in OncologyBladder AdenocarcinomaBladder Clear Cell AdenocarcinomaBladder Mixed Adenocarcinoma+42 more
RecruitingInterventional · Phase 2NCT04402151 ↗Single-Arm Phase II Study of PSMA PET/MR Guided Stereotactic Body Radiation Therapy With Simultaneous Integrated Boost (SBRT-SIB) for High-Intermediate and High Risk Prostate CancerSilvia Chiara FormentiPIInterventionDrug: PSMA PET/MR - Gallium-68 labeled PSMA-HBED-CC · Radiation: Stereotactic Body Radiation Therapy (SBRT)DatesJun 2020 – Dec 2027 (est.)SponsorWeill Medical College of Cornell UniversityProstate Cancer
Active, not recruitingInterventional · Phase 2NCT04422132 ↗Randomized Phase II Trial of Salvage Radiotherapy for Prostate Cancer In 4 Weeks v. 2 WeeksEmily WegPIInterventionRadiation: 5 days Radiation Therapy (32.5 Gy in 5 fractions) · Radiation: 20 days Radiation therapy (55 Gy in 20 fractions)DatesSep 2020 – Dec 2025· Results postedSponsorWeill Medical College of Cornell UniversityProstate Cancer
Active, not recruitingInterventional · Phase 2NCT04709276 ↗A Phase II, Single Arm Study of Chemoimmunotherapy for the Treatment of Men With Neuroendocrine or Aggressive Variant Metastatic Prostate Cancer (CHAMP)Cora SternbergPIInterventionDrug: Nivolumab · Drug: Ipilimumab · Drug: Carboplatin · Drug: CabazitaxelDatesJun 2021 – Feb 2026SponsorDuke UniversityMetastatic Prostate Neuroendocrine CarcinomaMetastatic Prostate Cancer
CompletedInterventional · Phase 2NCT02266745 ↗A Phase 1, Open-Label, Dose-Escalation Study Evaluating the Safety, Pharmacokinetics, and Clinical Effects of Intravenously Administered PT-112 Injection in Subjects With Advanced Solid Tumors and Subsequent Dose Expansion CohortsScott T. TagawaPIInterventionDrug: PT-112 InjectionDatesJul 2014 – Aug 2024 (est.)SponsorPhosplatin TherapeuticsAdvanced Solid TumorsCRPCmCRPC+6 more
TerminatedInterventional · Phase 2NCT04032704 ↗Open-Label Phase 2 Study of Ladiratuzumab Vedotin (LV) for Unresectable Locally Advanced or Metastatic Solid TumorsManish A ShahPIInterventionDrug: ladiratuzumab vedotin · Drug: pembrolizumabDatesOct 2019 – Nov 2023· Results postedSponsorSeattle Genetics, Inc.Small Cell Lung CancerNon-small Cell Lung Cancer, SquamousNon-small Cell Lung Cancer, Non-squamous+6 more
CompletedInterventional · Phase 2NCT04600336 ↗A Randomized, Double-Blind, Placebo-Controlled Phase II Study of Oxybutynin Versus Placebo for the Treatment of Hot Flashes in Men Receiving Androgen Deprivation TherapyScott T. TagawaPIInterventionDrug: Oxybutynin Chloride · Drug: Placebo Administration · Other: Quality-of-Life Assessment · Other: Questionnaire AdministrationDatesOct 2021 – Feb 2024· Results postedSponsorAlliance for Clinical Trials in OncologyProstate Carcinoma
TerminatedInterventional · Phase 2NCT04631744 ↗Open Label Phase II Trial of Cabozantinib in Patients With Metastatic Castrate Resistant Prostate Cancer (mCRPC) and Known Amplifications or Activating Mutations in Gene Targets of Cabozantinib or Liver Metastases Who Have Received Prior Anti-Androgen TherapyDavid M NanusPIInterventionDrug: CabozantinibDatesMar 2021 – May 2025· Results postedSponsorWeill Medical College of Cornell UniversityProstate Cancer
TerminatedInterventional · Phase 2NCT04984343 ↗Randomized Phase II Trial of Five or Two MRI-Guided Adaptive Radiotherapy Treatments for Prostate CancerEmily WegPIInterventionRadiation: Radiation TherapyDatesFeb 2022 – Dec 2025SponsorWeill Medical College of Cornell UniversityProstate Cancer